A revolution in weight loss treatment may force a reckoning for food and beverage companies

  • 📰 CNBC
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 72%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Morgan Stanley said a sizeable demographic representing a disproportionate share of food consumption will be changing their habits due to weight loss drugs.

If you have heard that new weight loss medications mean you can eat all the junk food you want and still lose weight — you've heard wrong. Still, it's undeniable that a huge shift is underway in how obesity and overweight is being treated by doctors due to a new class of drugs known as GLP-1 agonists. The drugs are more successful in achieving weight loss and appear to have fewer side effects than previous generations of obesity treatments.

Currently, it expects 40 million people have health insurance plans that would cover the medication. "Manufacturer supply constraints and the evolution of insurance coverage will likely impact broad [anti-obesity medication] accessibility, and this is a key question around use of these mediations," the analysts said. "It is unclear how insurance coverage will expand over time; it may depend on comorbidity trials .

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 12. in BR

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Morgan Stanley says buy 'top’ stocks like Apple to fight the growing market malaiseMorgan Stanley said it likes stocks like Apple as market uncertainty mounts.
Fonte: CNBC - 🏆 12. / 72 Consulte Mais informação »